Zyla life sciences (EGLT)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Operating activities:
Net (loss) income

-18,239

-6,224

-10,290

-19,643

-10,483

-

-

-

-

1,441

-18,948

-26,479

-25,373

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-18,548

-

-17,361

-17,087

-16,721

-8,466

-10,175

-11,657

-12,916

Adjustment to reconcile net (loss) income to net cash (used in) provided by operating activities:
Depreciation and amortization

3,698

3,700

3,701

3,705

2,470

-

-

-

-

1,244

1,250

1,139

1,429

1,371

1,042

883

822

747

785

851

631

175

155

143

168

Change in fair value of warrant and derivative liability

-

-

-

-

-

-

3,986

-

-

1,033

1,501

0

12

2

-11

43

610

-

-

-

-

-

-

-

-

Stock-based compensation expense

566

348

1,012

817

60

-

-

-

-

862

1,694

1,569

1,793

1,646

1,809

1,553

1,315

1,484

1,295

1,306

1,114

1,014

1,997

3,824

1,683

Non-cash interest and amortization of debt discount

470

955

2,225

1,977

954

-

-

-

-

481

1,534

1,584

1,471

1,892

1,426

430

2,163

-

-

-

-

-

-

-

-

Noncash interest and amortization of debt discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,138

1,402

128

-

-

-

-

Accretion of discount on marketable securities

-

0

0

0

-3

-

-

-

-

-69

-11

31

25

58

98

149

302

-

-

-

-

-

-

-

-

Change in right of use assets

193

213

-1,308

168

109

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of contingent consideration

4,000

1,288

795

2,700

200

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Impairment of goodwill

4,830

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of debt discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6,987

Deferred income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-281

-358

-237

-185

-722

0

-22

26

-

-

-

-1

Changes in assets and liabilities:
Related party receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

2

0

-1

-58

-40

-435

121

-209

545

-146

205

140

Accounts receivable

5,365

-881

5,362

-18,727

35,802

-

-

-

-

-1,487

500

-303

4,302

-2,782

3,070

-9

534

-

-

-

-

-

-

-

-

Inventory

1,232

-489

-5,047

-8,691

-10,562

-

-

-

-

1,390

-114

438

-189

213

-255

-395

300

-1,715

-335

439

40

-

-

-

-

Prepaid expenses

-657

2,535

-613

-1,077

-686

-

-

-

-

1,272

31

-209

-962

671

725

-473

320

-654

1,300

-437

422

-99

313

-133

459

Other receivables

64

813

-157

160

-131

-

-

-

-

-269

-71

84

37

-236

195

-1,106

1,119

-

-

-

1

-

-

-

-

Deposits and other assets

-768

-103

-178

1,272

476

-

-

-

-

-42

-627

968

76

695

-1,619

-128

-429

762

1,502

-222

8

-

-

-

-

Accounts payable

10,348

-3,054

8,797

-4,558

3,231

-

-

-

-

4,364

2,443

-3,503

4,293

-3,318

419

649

-695

1,871

-254

760

-1,230

2,934

-1,193

1,287

240

Accrued expenses

4,957

728

40

-9,328

12,142

-

-

-

-

-1,852

-3,364

6,207

-3,123

4,249

4,907

1,267

130

2,528

-404

1,047

1,952

-290

1,383

872

-553

Deferred revenue

-

-

-

-

-

-

-

-

-

-1,303

2,569

9

2,200

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-933

-2,273

-1,190

-1,757

-19,930

-1,709

8,582

14,542

-147

-148

-147

-115

Other current liabilities

45

204

-213

-49

13

-

-

-

-

-

-2

2

1

-498

116

139

56

120

-50

63

-17

5

8

-6

25

Other liabilities

-306

-288

1,393

-229

-194

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other liabilities

-

-

-

-

-

-

-

-

-

-45

-44

-44

-46

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) operating activities

5,326

-3,972

6,785

2,623

-16,400

-

-

-

-

-9,996

-14,099

-20,463

-20,606

-

-

-

-

-

-

-

-

-

-

-

-

Investing activities:
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-18,793

-

-18,688

-2,225

163

-6,100

-8,137

-5,756

-5,081

Payments for purchase of property and equipment

3

16

0

18

6

-

-

-

-

-2

-27

53

64

-1,837

2,812

2,652

3,610

2,043

30

511

163

2,462

-55

397

85

Deposits for purchases of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

111

Purchases of investments

-

-

-

-

-

-

-

-

-

7,947

37,446

0

55,945

14,023

4,428

14,381

26,713

-

-

-

-

-

-

-

-

Sales of investments

-

0

0

0

2,497

-

-

-

-

-

-

-

-

5,800

3,170

3,000

2,400

-

-

-

-

-

-

-

-

Maturity of investments

-

0

0

0

2,500

-

-

-

-

12,350

22,000

17,297

20,000

20,275

15,200

32,041

33,761

-

-

-

-

-

-

-

-

Purchase of SPRIX Nasal Spray

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

8,128

-

-

-

-

License of OXAYDO

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,500

0

0

5,172

-

-

-

-

Net cash (used in) provided by investing activities

-3

-3

0

-18

4,991

-

-

-

-

4,405

-6,624

20,644

-36,009

-

-

-

-

-

-

-

-

-

-

-

-

Financing activities:
Net proceeds from issuance of common stock

-

-

-

-

-

-

-

-

-

384

28,695

2,802

1,007

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from IPO, net of costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

53,124

Net proceeds from issuance of common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

13,950

Payments of contingent consideration

1,600

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payments on borrowings

1,125

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payments of tax withholdings on restricted stock

90

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from credit agreement

-

0

-77

-928

4,775

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net proceeds from debt and royalty rights

-

-

-

-

-

-

-

-

-

0

0

0

38,304

-

-

-

-

-99

0

56,883

14,613

-

-

-

-

Net cash (used in) provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5,838

-

-42,616

-51,541

-13,463

-927

-317

-2,303

-196

Royalty payments in connection with the 13% Notes

-

-

-

-

-

-

-

-

-

0

161

0

146

-

-

-

-

-

-

-

-

-

-

-

-

Net cash (used in) provided by financing activities

-2,815

-2,624

-309

-928

4,775

-

-

-

-

-1,148

28,534

2,802

39,165

-

-

-

-

-

-

-

-

-

-

-

-

Effect of foreign currency translation on cash and cash equivalents

69

-30

64

-10

-26

-

-

-

-

79

71

298

82

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) cash, cash equivalents and restricted cash

2,577

-6,629

6,540

1,667

-6,660

-

-

-

-

-6,660

7,882

3,281

-17,368

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

80,783

56,965

14,613

0

0

-92

67,074

Effect of foreign currency translation on cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

457

-

13

580

-164

40

-1,080

-40

-47

Net decrease in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,267

11,601

854

-12,498

-30,493

19,492

3,779

1,149

-

-

-

-

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-6,987

-9,534

-8,191

61,750

Supplemental disclosures of cash flow information:
Conversion of convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

14,957

Issuance of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

329

-

-

-

-

Cash interest payments

120

-

-

-

-

-

-

-

-

2,155

5,200

1,678

3,784

1,148

1,152

370

2,042

915

1,982

360

204

-

-

-

-

Non-cash financing activities:
Conversion of related party convertible debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

24,713

Liability for contractual payment associated with OXAYDO license

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

2,500

-

-

-

-

Predecessor
Net (loss) income

-

-

-

-

-

-

-

-11,962

-12,354

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

-

-

-

-

-

-

-

1,197

1,210

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of warrant and derivative liability

-

-

-

-

-

-

-

3,181

5,125

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation expense

-

-

-

-

-

-

-

1,002

952

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest and amortization of debt discount

-

-

-

-

-

-

-

746

496

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of discount on marketable securities

-

-

-

-

-

-

-

-47

-97

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts receivable

-

-

-

-

-

-

-

-5,900

11,234

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Inventory

-

-

-

-

-

-

-

1,070

-955

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses

-

-

-

-

-

-

-

-694

-439

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other receivables

-

-

-

-

-

-

-

25

-2

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deposits and other assets

-

-

-

-

-

-

-

0

-164

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

-

-

-

-

-

-

-

-1,384

-19

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued expenses

-

-

-

-

-

-

-

2,830

3,995

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other liabilities

-

-

-

-

-

-

-

-47

-44

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash (used in) provided by operating activities

-

-

-

-

-

-

-

-5,348

-20,660

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payments for purchase of property and equipment

-

-

-

-

-

-

-

6

3

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of investments

-

-

-

-

-

-

-

19,186

4,265

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Maturity of investments

-

-

-

-

-

-

-

27,900

23,500

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by investing activities

-

-

-

-

-

-

-

8,708

19,232

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net proceeds from issuance of common stock

-

-

-

-

-

-

-

891

4,157

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Royalty payments in connection with the 13% Notes

-

-

-

-

-

-

-

0

201

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) financing activities

-

-

-

-

-

-

-

891

3,956

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Effect of foreign currency translation on cash and cash equivalents

-

-

-

-

-

-

-

-101

61

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net (decrease) increase in cash, cash equivalents and restricted cash

-

-

-

-

-

-

-

4,150

2,589

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash interest payments

-

-

-

-

-

-

-

0

5,878

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Reclassification to additional paid-in capital of derivative liability

-

-

-

-

-

-

-

0

12,497

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-